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If left untreated, hypercholesterolaemia can lead to atherosclerosis, given time. Plants from the Fabaceae family have shown the
ability to significantly suppress atherosclerosis progression. We selected four extracts from Pithecellobium ellipticum, from the
Fabaceae family, to be screened in a 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA reductase) assay. The ethanol
extract, at a concentration of 500 𝜇g/mL, exhibited superior inhibition properties over the other extracts by demonstrating 80.9%
inhibition, while 0.223 𝜇g/mL of pravastatin (control) showed 78.1% inhibition towards enzymatic activity. These findings led to
the fractionation of the ethanol extract using ethyl acetate :methanol (95 : 5), gradually increasing polarity and produced seven
fractions (1A to 7A). Fraction 7A at 150 𝜇g/mL emerged as being the most promising bioactive fraction with 78.7% inhibition.
FRAP, beta carotene, and DPPH assays supported the findings from the ethanol extract as it exhibited good overall antioxidant
activity.The antioxidant properties have been said to reduce free radicals that are able to oxidize lipoproteins which are the cause of
atherosclerosis. Phytochemical screenings revealed the presence of terpenoid, steroid, flavonoid, and phenolic compounds as the
responsible group of compound(s), working individually or synergistically, within the extract to prevent binding of HMG-CoA to
HMG-CoA reductase.
1. Introduction
Hypercholesterolaemia is the main contributor to numerous
cardiovascular diseases (CVD) with substantial data from
studies to support this claim [1, 2]. It is predicted that over
a billion deaths will be due to CVD by the earlier half of
the 21st century [3]. Mackey and Co. (2007) estimated that
approximately 18.1 million deaths were due to cardiovascular
disease in 2010 and that we will see an increase of 33.7% by
2030.
Hypercholesterolaemia can lead to atherogenesis. Ath-
erosclerosis is the primary risk factor for coronary heart
disease and affects the peripheral arteries and cerebral
circulation. Studies relating to cancer and total cholesterol
levels have shown that the total cholesterol level is the main
risk factor for disease. However, most of the cholesterol is
carried in the plasma (60–70%), in the form of low density
lipoproteins (LDLs) and it is this which is themain risk factor
for disease [4, 5].
Overproduction of reactive oxygen species has been
strongly associated to the development of oxidation related
conditions like atherosclerosis and cardiovascular diseases [5,
6]. Atherosclerosis beginswith the transmigration of oxidized
LDLs to the intima (the subendothelial space) which cause
injuries to endothelial cells.The injury is described as cellular
damage and one result of this type of damage is the loss of
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function of the cell [4, 7, 8]. Endothelial cells respond to
the injury by becoming sticky which alerts the macrophages
to ingest the oxidized LDLs. These macrophages are then
overloaded with oxidized LDLs; the appearance of the lipids
in the macrophages gives them a foamy appearance; hence
they are given the name “foam cells.” The accumulation
of foam cells leads to the formation of fatty streaks [7].
After some time atheroma takes place, the smooth muscle
cells migrate and further restrict the blood flow leading to
atherosclerosis. Complex lesions occurwith the advancement
of inflammatory responses, necrotic core formation, and
death of foam cells. Finally, thrombosis occurs when fibrous
caps rupture [4, 7–9]. 3-Hydroxy-3-methylglutaryl coenzyme
A reductase (HMG-CoA reductase) is the rate limiting
factor for the formation of mevalonate in the cholesterol
biosynthesis pathway. This enzyme has been chosen as one
of the pharmacological targets to control the production
of cholesterol de novo. Statins are widely used to treat
hypercholesterolaemia because of their ability to exhibit
superior suppression of lipid synthesis at a nanomolar scale
[10]. The hydrophobic group of a statin is suggested to
be the core reason for this nanomolar inhibition constant
value, 𝐾
𝑖
∼ 1 × 10
−9M, while the substrate’s 𝐾
𝑚
value is
∼ 10
−5M [10, 11]. This gives the enzyme a 10,000-fold higher
binding affinity towards statins compared to the substrate
[10].
Generally, a statin’s heptatonic acid functional group
resembles the HMG moiety of the substrate at the molec-
ular level. Istvan and Deisenhofer (2001) proved that the
heptatonic acid can be easily competed with and bound
at the O5-hydroxyl group of the HMG-like moiety and
that it replaced the thioester oxygen atom of the substrate.
The conformational flexibility has sterically hindered the
substrate from binding with the enzyme. Concurrently, the
statin structure extends into the narrow pantothenic acid-
binding pocket moiety of coenzyme A which eventually
blocks the coenzyme A of the substrate [11, 12]. This is why
statins are capable of competing with the substrate.
Besides effectively interfering with cholesterol biosynthe-
sis via inhibiting the reductase enzyme, statins are gaining
attention for their antiatherosclerosis effect due to their
antioxidant ability. A few of the statins’ antioxidant defense
mechanisms include reducing lipoprotein cholesterol which
reduces substrate oxidation, attenuating development of
superoxide anions in endothelial cells to prevent oxidation of
LDLs and preventing diffusion of free radicals produced from
oxidative stress towards the lipoprotein core [13]. Fluvastatin
sodium has shown such ability [14].
Currently available cholesterol lowering drugs such as
statins do pose a risk of myopathy by depressing ubiquinone
Q
10
biosynthesis, rhabdomyolysis, and other considerable
side effects like comorbidities and several noncardiac effects
(gratuitous thoughts, short temper), psychiatric events, and
even impairment of the central nervous system [15, 16]. This
opens a need for more research into natural product such
as plants from the Fabaceae family [2]. Pithecellobium sp.
shrubs and trees are distributed in the secondary forests and
riverbanks of Tropical Asia and Subtropics of America [17–
22]. Approximately 200 species have been identified from this
genus [23]. This genus exhibited antifungal [24–27], antibac-
terial [25, 27], anti-inflammatory [28], antiallergic effects
[28], insect antifeedant [29], piscicide [30], and antioxidant
activity [31–34].
Pithecellobium ellipticum is also known as Archidendron
ellipticum (Blume) I. C. Nielsen and commonly called kabau
(Jering tupai) in Malaysia [22]. Wild fruits of P. ellipticum
are enjoyed by Malaysians in salad and cooking due to
their delicious flavor [10]; they are used as an astringent in
Indonesia [21], as a remedial shampoo in Java, and as fish
poison [35]. This particular plant has not been thoroughly
studied for its lipid-lowering properties. A T. indica ethanol
extract from the same family has been reported to decrease
non-HDL cholesterol by 73%, triglycerides by 60%, and even
increaseHDLcholesterol up to 61% [2, 9]. Besides this, radical
scavenging tests disclosed that in some in vivo studies the
extract improved antioxidant abilities in an animal model
[9]. These findings indicate that the properties within the
extract are capable of reducing atherosclerosis. The aim of
this study is to assess the HMG-CoA reductase inhibition
ability, antioxidant properties, and screening for the presence
of secondary metabolites from the crude extract of the leaves
of P. ellipticum (code: UNMC 35L).
2. Results and Discussion
All of the extracts prepared only with the extract and buffer
showed absorption at 340 nm in the spectrophotometric
analysis (results not shown). This is not a surprise as crude
extracts are expected to contain numerous compounds.
Therefore, all extracts require colour correction to ensure all
possible interfering absorbances contributed by the extracts
in the HMG-CoA reductase assay are minimized.This is also
important as NADPH molecules absorb light at the same
wavelength and their oxidized form NADP+ does not [36].
This is the reason why this enzymatic assay was analyzed at
340 nm and requires minimal interference at 340 nm from
the samples analyzed.
Table 1 shows the specific activity and percentage of
inhibition of all the crude extracts. Any specific activity
obtained lower or near the pravastatin range is considered
to have the ability to inhibit HMG-CoA reductase activity.
Values near or above the negative control’s specific activity
implies that the particular sample either is a very weak
inhibitor or may elevate the enzymatic activity. The ethanol
(E) extract stood out as the extract with the most potential
followed by the water (W), ethyl acetate (EA), and finally
hexane (H) extract with the least inhibitory capability. The
specific activity of the E extract was calculated as being 21.8
times lower than that of the H extract, making it a superior
inhibitor to the H extract.
The difference in inhibition competency between E and
W extracts was 17.8%.This might be due to the concentration
of active compounds present within the E extract being
greater or that the competition for the active moiety favors
the E extract over the W extract. Another probability would
be the binding locations; bonds and presence of inhibitor
active moiety involved in the inhibitor-enzyme complex are
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Table 1: Percentage of inhibition of UNMC 35L crude extract.
Sample Specific activity(units/mg protein) % inhibition
H crude extractA 5.668 ± 2.9a 0
EA crude extractA 3.638 ± 3.0b 0
E crude extractA 0.260 ± 0.6ac 80.9
W crude extractA 0.503 ± 0.5ad 63.1
Positive control (pravastatin)B 0.298 ± 0.3abe 78.1
Negative control 1.363 ± 0.5af 0
Values with the same letter are significantly different P < 0.05 by Tukey’s
multiple comparison tests.
Results are demonstrated as average ± standard deviation (n = 2 : 3 different
experiments).
ACrude extracts are prepared at a concentration of 500𝜇g/mL.
BPravastatin is prepared at a concentration of 0.223𝜇g/mL.
sturdier and not easily broken. For example, the constituents
in the E extract might have attached firmly at the active
pocket, while constituents within the W extract bind weakly
instead. Additionally, a different pharmacological activity
is contributed by an inhibitor’s active moiety, such as that
which is present in Pitavastatin [37]. The inhibition value
of the E extract at 80.9% was comparable to pravastatin
(78.1%) even though the concentration used was distinctively
huge. It is essential to realise that even though 500𝜇g/mL is
considered a high concentration, this is the concentration of
the crude extract and the active compound within the extract
is hypothesized to express this suppression ability at a much
lower concentration. Another key finding from Figure 1 is
that the W extract which appeared to have some suppressing
activity (0.503 units/mg protein) became noticeably weaker
over the duration of 10 minutes. The line graph of the W
extract is above the negative control line on the graph. This
means that the concentration of the active compound within
the W extract is exhausted and the activity is reversible,
allowing the natural substrate to take over once again and
bind with the HMG-CoA reductase.
Thefinding attained from the extract inhibitory screening
has led to the fractionation of the ethanol extract as it had the
highest suppressing strength.The resulting fractionation pro-
duced 7 fractions labeled 1A–7A. Fractionation was carried
out with increasing solvent polarity. Fraction 7A (consisting
of the last thirteen vials from fractionation) was found to be
the most promising fraction in influencing the HMG-CoA
reductase activity (Table 2 and Figure 2).
Fraction 7A had the highest inhibition activity (78.7%)
with a specific activity of 0.211 ± 0.2 units/mg protein
(Figure 2(a) is expended for viewing purpose). Twofold
dilutions of 7A were prepared to reveal the effectiveness of
this fraction. It showed an apparent trend with increasing
solvent polarity used for fractionation; the fractions achieved
higher inhibitory properties as seen from fractions 3A to 7A.
In contrast, 5A did not comply with the trend by disclosing
only 16.3% inhibition.
Statistical analysis indicated that twofold dilution samples
of 7A labeled 7A-1 to 7A-4 actually have no significant
difference between them or pravastatin (Figure 2(b)), but
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Figure 1: HMG-CoA reductase specific activity of crude extracts.
Table 2: Percentage of inhibition of UNMC 35L ethanol fractions.
Fractions Specific activity(units/mg protein) % inhibition
1AA 2.744 ± 0.9 0
2AA 0.812 ± 0.6 18.0
3AA 0.974 ± 0.6 1.6
4AA 0.552 ± 1.0 44.2
5AA 0.829 ± 0.6 16.3
6AA 0.520 ± 0.4 47.5
7AA 0.211 ± 0.2 78.7
Positive control (Pravastatin)B 0.195 ± 0.3 100.0
Negative control 1.234 ± 0.8 0
All values are not significantly different P < 0.05 by Tukey’s multiple
comparison tests.
Results are demonstrated as average ± standard deviation (n = 2 : 3 different
experiments).
A1A to 7A fractions are prepared at a concentration of 150 𝜇g/mL.
BPravastatin is prepared at a concentration of 0.223𝜇g/mL.
pravastatin concentration was kept at 0.223 𝜇g/mL. Despite
this, mL7A-2 exhibited higher inhibition activity compared
to 7A-1 which was not expected. 7A-3 and 7A-4 fractions did
not express any distinct difference to 7A-1. Six different phyto-
chemicals, including saponins, flavanoids, tannins, phenols,
terpenoids, and steroids, were screened for, to find out
which secondary metabolites were present. Phytochemical
screening results for P. ellipticum were in agreement with
the isolation of saponins from leaves that was reported
earlier by Beutler et al. [18]. The hexane extract consisted
of flavanoids and terpenoids, while the EA extract had
tannins, terpenoids, and steroids. The E extract had positive
reactions in all tests except for tannins.Meanwhile, flavanoids
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Figure 2: (a) HMG-CoA reductase specific activity on 35L E 1A–7A fractions; (b) HMG-CoA reductase specific activity on UNMC 35L 7A
twofold dilution.There is no significant difference with 𝑃 < 0.05 in Tukey’s multiple comparison tests. Results are demonstrated as average ±
standard deviation (𝑛 = 2 : 3 different experiments).
Table 3: Phytochemical screenings of UNMC 35L crude extracts.
Types of screenings Leaves extracts
H EA E W
Saponins − − + +
Flavonoids + − + −
Tannins − + − +
Phenolic contents − − + +
Terpenoids + + + +
Steroids − + + −
Results expressed as + and – indicate, respectively, the presence and absence
of secondary metabolites within the crude extracts.
and steroids were absented in the W extract. There is a
possibility that the flavonoid, phenolic content, terpenoid,
and steroid compounds are responsible (Table 3) for effective
competition with the substrate, for binding at or blocking the
substrate from binding at the enzyme’s narrow pocketmoiety.
Saponins are an exception in this enzymatic discussion
because saponins are categorized as a bile acid sequestrant
that works within the intestines [38]. Thus, this eliminates
the possibility of saponins suppressing the reductase activity
in the inhibitory assay that was conducted. Saponins have
been reported to elevate the activity and expression of
hepatic lipase located at the liver and inhibit the mRNA
and expression of fatty acid synthase to reduce lipids in a
hyperlipidaemic animal model [38].
Lipid peroxidation involves the forming and spreading
of reactive oxygen species (ROS). Lipid hydroperoxides are
produced in the presence of oxygen in lipid oxidation. ROS
lead to oxidative stress that also induces atherosclerosis and
which makes the antioxidant analyses a very important part
of our investigation, especially in the case of the E extract
in determining whether it truly possesses antioxidant prop-
erties. Three antioxidant assays, FRAP, 𝛽-carotene bleaching
assay, and DPPH, were conducted on the crude extracts
and recorded in Table 4. Lipid peroxidation began with Fe3+
and tripyridyl triazine (TPTZ). Extracts with antioxidant
properties successfully reduce Fe3+ to Fe2+. With regards
to the FRAP assay values, the E extract had the highest
antioxidant activity with 0.843mmol FeSO
4
equivalent/L and
followed by the EA, W, and lastly H extract.
Inhibition of oxidation in the 𝛽-carotene bleaching assay
samples are arranged in decreasing order: W > H > E >
EA. EC
50
of the W extract was 4.631 × 10−5 𝜇g/mL which
appeared to be more effective than quercetin and only two
times weaker than Trolox. This reveals that the potential
antioxidant compound isolated from the W extract might be
even more potent than Trolox. Both H and extracts however
demonstrated roughly similar abilities in protecting the 𝛽-
carotene compound; meanwhile the H extract proved to be a
poorer antioxidant extract in the FRAP assay with 16.96 times
lower antioxidant activity than the E extract.
DPPH results have wider IC
50
values ranging between
460.930 and 12.738 𝜇g/mL. The EA extract showed the
greatest free radical scavenging activity with an IC
50
of
12.738 𝜇g/mL and this value does not differ much from that
of the E extract (approximately 1.09 times more powerful).
Trolox (1.09 𝜇g/mL) was 12.7 times stronger than the E
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Table 4: Different types of antioxidant analyses.
Crude samples
Type of analysis
FRAP 𝛽-Carotene DPPH
mmol FeSO4 equivalent/L R2 EC50 (𝜇g/mL) IC50 (𝜇g/mL)
Hexane 14.301 ± 0.0ad 1.0000 7.188 × 10−3a 460.930 ± 0.2a
Ethyl acetate 1.093 ± 0.7ab 0.9812 1.775 × 10−2a 12.738 ± 0.4ab
Ethanol 0.843 ± 0.1ac 0.9453 1.059 × 10−3a 13.830 ± 0.0ac
Water 1.240 + 0.3ad 0.9964 4.631 × 10−5ab 145.403 ± 0.1ad
Quercetin 0.003 ± 0.1ade 0.9992 1.132 × 10−4ac 0.110 ± 0.0ae
Trolox 0.010 ± 0.0adf 0.9906 9.730 × 10−5ad 1.090 ± 0.0af
Values in the same column that are followed by the same letter are significantly different P < 0.05 by Tukey’s multiple comparison tests.
Results are expressed as means ± S.D (n = 2 : 3 different experiments).
extract. The H extract was the least potent of all (IC
50
=
460.930 𝜇g/mL). The ethyl acetate and ethanol extracts were
ranked as themost and second potent-free radical scavengers,
respectively, while the W extract belongs to the intermediate
antioxidant group obtaining an IC
50
of 145.403 𝜇g/mL. The
H extract had the lowest free radical quenching capacity.
An interesting note is that the E extract was the most
potent inhibitor in the HMG-CoA reductase assay and has
consistently exhibited strong antioxidant activity in the three
assays conducted. However, other extracts demonstrated
potent antioxidant activity in certain assays but not in others.
No consistently low values were found in the assays for the
poorly active extracts except for the H extract which was the
weakest in both FRAP and DPPH assays. The ethyl acetate
extract had the greatest activity in both FRAP and DPPH
assays meanwhile the W extract was, strongest in the 𝛽-
carotene bleaching assay.
Their antioxidant properties are expected to correlate
with the results of the phytochemical screenings. This would
be due to phenolic compounds and their derivatives that are
capable of preventing auto-oxidation. Phenolic compounds
are bioactive substances that are recognized for their antioxi-
dant ability. From the correlation of results, components from
7A fraction might contain antioxidant properties in addition
to its enzyme inhibition ability.
This antioxidant compound from the active extracts may
potentially be capable of affecting both free radicals from
causing oxidative stress and the enzyme activity, reduc-
ing atherosclerosis progression in hypercholesterolaemic
patients as statins do. Statins have been tested in various
antioxidant assays to demonstrate their ability in reducing
atherosclerosis in ways other than directly inhibiting HMG-
CoA reductase [39, 40]. The antioxidant compound(s) from
this plant that is responsible for interrupting HMG-CoA
reductase in the assay might behave similar to statins. Reduc-
tion of Fe3+-TPTZ complex to Fe2+-TPTZ complex could be
caused by chain termination of peroxyl and hydroxyl radical
formation caused by the antioxidant compounds, especially
in the active extract. Lovastatin and simvastatin have been
shown to stimulate formation of Fe2+ [39].
Statins which are synthesized or naturally isolated have
demonstrated different lipid peroxidation and scavenging
activity. Another possibility would be that the functional
group present within the compound itself from P. ellipticum
exerts an antioxidant ability like in the case of the enolmoiety
conjugated to the indole ring of fluvastatin sodium [14]. The
hydrophobic side chain of the potential active compound is
a contributing factor to the potency of the binding affin-
ity towards HMG-CoA reductase. Furthermore, the same
antioxidant compound could also donate an electron to the
free radicals through scavenging activity as reported in the
cases of simvastatin and rosuvastatin [39].
3. Materials and Methods
3.1. Plant Material and Extraction Procedure. Leaves of
P. ellipticum were collected from Sungai Congkak Forest,
Malaysia. The plant authenticity was verified and herbarium
specimen deposited at Forest Research Institute Malaysia
(FRIM) with voucher number of PID160610-06. A portion of
plant material (232 g) was macerated with hexane overnight
in a ratio of 1 : 8 (plant material : solvent) and extracted three
times. This extraction process was subsequently repeated
using ethyl acetate, ethanol, and finally water. Combined
extracts yielded H (0.46%), EA (1.48%), E (1.72%), and W
(4.83%).
3.2. Qualitative Analysis by UV-Vis Spectrometer. All the
crude extractswere prepared at 500 𝜇g/mL and scannedusing
PerkinElmer, Lambda 25model to monitor colour correction
at 340 nm. Extracts showing chromophore and auxochrome
at 340 nm region were prepared for colour correction.
3.3. HMG-CoA Reductase Assay. HMG-CoA reductase assay
kit was purchased from Sigma Malaysia. The kinetic activity
measurements were carried out in triplicate and determined
by employing the spectrophotometricmethod fromSigmaCS
1090 with minor modifications. 500𝜇g/mL (crude extracts)
and 150 𝜇g/mL and its twofold dilutions (fractions) were
dissolved in dimethyl sulphoxide, DMSO (Labscan). Assay
kit components were incubated for 15 minutes at 37∘C prior
to analysis. A different amount of 1 X assay buffer was added
(blank: 183 𝜇L, inhibitor: 181𝜇L, activity: 182 𝜇L, samples:
182 𝜇L, and sample correction: 199 𝜇L), 1 𝜇L DMSO was
added to the blank, inhibitor, and activity wells, 1𝜇L of
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pravastatin into inhibitor wells, 4 𝜇L of NADPH, and 12 𝜇L
substrate were added into all wells and incubated for another
5 minutes. Finally, 2 𝜇L of reductase enzyme was added.
Samples were prepared in duplicate. The kinetic study was
analyzed at 340 nm and at 37∘C with the shake mode on for
10 minutes using Varioskan Flash (Thermofisher). Specific
activity was expressed in unit/mg protein:
unit
mg protein
=
(Δ𝐴
340
/minsample − Δ𝐴340/mincontrol) × TV
12.44 × 𝑉 × 0.6 × LP
(1)
12.44 = 𝜀𝑛𝑀—the extinction coefficient for NADPH at
340 nm is 6.22m/Mcm. 12.44 represents two NADPH con-
sumed in the reaction. TV: total volume of the reaction in
mL (0.2mL for plates), V : volume of enzyme used in the
assay (mL), 0.6: Enzyme concentration in mg-protein (mg
protein)/mL that is 0.55–0.65mg protein/mL, and LP: light
path in cm (0.55 for plates).
3.4. Fractionation of the Ethanol Extract. The ethanol extract
(1.4 g) was chosen for further fraction. Silica 60 (Merck,
0.063–0.200mm) was used as the packing material with
the ratio of 1 g sample : 50 g silica. Starting solvent system
was ethyl acetate :methanol (95 : 5) increasing the methanol
gradually, followed by ethanol, 1% of acetic acid, and finally
2% of acetic acid in ethanol. A total of 113 fractions were
collected and combined into seven major fractions (35L E
1A to 7A) after thin layer chromatography profiles were
determined with different ratios of chloroform-methanol,
ethyl acetate-methanol, and butanol-acetic acid-water sol-
vent systems using detection under UV light, iodine vapor,
vanillin, ferric chloride, and antimony (III) chloride spray
reagents. All fractions (150 𝜇g/mL and its two-fold dilutions)
were later subjected to the HMG-CoA reductase assay to
determine the active fractions.
3.5. Phytochemical Screenings. Several tests were performed
to confirm the presence and identity of secondarymetabolites
within the crude extracts: saponins, flavonoids, tannins,
phenolics, steroids, and terpenoids. Approximately 12.5mg of
each extract was prepared.
3.5.1. Test for Saponins (Frothing Method). Each extract was
dissolved in 5mL of purified water in the test tube and
covered with cork according to method by H. A. Ibrahim
and H. Ibrahim. The samples were sonicated for 15 minutes
at 40∘C. Samples that had particles were filtered before being
shaken vigorously for thirty seconds and then left for another
45minutes. Persistent froth revealed the presence of saponins
[41].
3.5.2. Test for Flavonoids (Modified Shinoda Test). Flavonoid
analysis was prepared following the Modified Shinoda Test
[42]. All extracts were dissolved in 5mL of DMSO. 3-4 cm of
magnesium turnings and 6 drops of 36% concentrated HCl
were added. Various colours such as orange, pink, and red to
purple represent flavones, flavonols, 2,3-dihydro derivate, and
xanthone, respectively.
3.5.3. Test for Tannins and Phenolic Content (Gelatin Pre-
cipitation and Ferric Chloride). This test by Mojab and
colleagues used two reagents: gelatin solution for protein
precipitation and ferric chloride to confirm the presence of
phenolics. Extracts were dissolved in 5mL purified water and
sonicated for 15 minutes at 40∘C. The volume was divided
into three portions—one for control, gelatin precipitation,
and phenolics. White fog or precipitation with 5mL of 1%
gelatin indicates the presence of tannins, while a change from
colourless to brownish-green or a blackish-blue colour after 6
drops of 1% ferric chloride indicates the presence of phenolics
[43].
3.5.4. Test for Steroids/Terpenoids (Salkowski Test). Both
steroid and terpenoid tests were accomplished using the
Salkowski test [44, 45]. Every extract was dissolved in 5mL
of DMSO and sonicated for 15 minutes at 40∘C. One mL of
solution was added to 1mL chloroform and an equal volume
of concentrated sulphuric acid was slowly added down the
side of the test tube. The upper layer changed to a red colour
and the sulphuric acid layer displayed a yellow colour with
green fluorescence. A reddish-brown colour observed at the
interface corresponded to the presence of terpenoids, while
a blue or green interface indicated the presence of steroid
compounds.
3.6. Antioxidant Assays Evaluation. All crude extracts were
dissolved in DMSO. Quercetin and trolox were used as
standards.
3.6.1. Ferric Reducing Ability Power (FRAP) Assay. The rea-
gents were prepared according to the reports of Benzie and
Strain. 180 𝜇g/mL fresh FRAP was pipetted and followed
by 20𝜇L of the sample (in triplicate). The microplate was
incubated for 90 minutes prior to being monitored spec-
trophotometrically at 593 nm through a Dynex Microplate
Reader. Concentrations ranging from 1 to 125mM of ferric
sulphate concentrations were prepared for calibration. FRAP
values were expressed as the concentration of the extracts that
showed an absorbance value equal to 1mM of FeSO
4
[46].
3.6.2. 𝛽-Carotene Bleaching Method. This experimental pro-
cedure was slightly modified from Miller [47]. Two mg of
𝛽-carotene was dissolved in 10mL CHCl
3
. Then 2mL was
pipetted into a 100mL round bottom flask and CHCl
3
was
later removed. Subsequently, 40mg purified linoleic acid;
400mg Tween 80 emulsifier; and 100mL distilled water
were added and shaken. Readings were measured at 490 nm
with a Dynex Microplate Reader at 20 minute intervals
and incubated at 50∘C for four hours. Both the blank and
wells without 𝛽-carotene solution were used for background
subtraction. The following equations were used to calculate
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the rate of degradation and antioxidant activity. EC
50
value
calculated represents 50% antioxidant ability:
Sample degradation rate = ln(
Abs
𝑡=0
Abs
𝑡=240
) ×
1
240
,
Antioxidant activity,%
= 100% × (
degradationcontrol − degradationsample
degradationcontrol
) .
(2)
3.6.3. Free Radical Scavenging Activity. Twenty microliters
of (0.003 up to 1mg/mL) samples were added with 180 𝜇L
(0.1mM) DPPH (2,2-diphenyl-1-picrylhydrazyl). Scavenging
activity absorbance was performed at 550 nm via Varioskan
after incubating for 30 minutes in the dark, at room temper-
ature [48]. The antioxidant activity was presented as the IC
50
which is 50% of the crude extract concentration required for
quenching free radicals. Initially the samples were purple and
decoloration to yellow (reduced form of DPPH) disclosed the
presence of the scavenging potential of the antioxidant extract
[49]:
DPPH inhibition,% = 100 × (
Abscontrol/Abssample
Abscontrol
) . (3)
3.7. Statistical Analysis. Thestatistical analysiswas performed
using GraphPad Prism 5.02 Software.The data was compared
with analysis of variance, ANOVA, and Tukey Multiple
Comparison Test as the posttest. Probability value of 𝑃 <
0.005 was selected for significant difference.
4. Conclusions
Through the HMG-CoA reductase assay, the ethanol extract
of Pithecellobium ellipticum revealed itself to be a promising
hypercholesterolaemic lowering agent. The responsible com-
pounds might be flavonoids, phenolics, terpenoids, or even
steroids. Negative results in the phytochemical screening
might have been due to either the secondary metabolite not
being present or being present in a minute amount which
could not be detected. Overall, the ethanol extract exhibited
good antioxidant ability in the three antioxidant assays. Of
course, further tests will be required to confirm whether the
active component is also an antioxidant substance.Additional
isolations and identifications are being carried out for frac-
tion 7A to find the constituents that are able to influence
HMG-CoA reductase activity.
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